Principal Technologies Inc.

Equities

PTEC

CA74260Q1028

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 11:00:00 2024-04-16 am EDT			5-day change	1st Jan Change
0.15 ^CAD	-.--%		-.--%	+11.11%

Apr. 03	Principal Technologies Announced Loan Financing and Private Placement and Updated On Vivostat A/S Acquisition	MT
Apr. 03	Principal Technologies Inc. announced that it expects to receive CAD 1 million in funding	CI

Principal Technologies Inc. Reports Earnings Results for the Full Year Ended July 31, 2023

December 30, 2023 at 06:33 pm EST

Principal Technologies Inc. reported earnings results for the full year ended July 31, 2023. For the full year, the company reported sales was CAD 0.425632 million compared to CAD 0.339345 million a year ago. Net loss was CAD 1.03 million compared to CAD 1.35 million a year ago.

Basic loss per share from continuing operations was CAD 0.06 compared to CAD 0.08 a year ago.

Latest news about Principal Technologies Inc.

Principal Technologies Announced Loan Financing and Private Placement and Updated On Vivostat A/S Acquisition	Apr. 03	MT
Principal Technologies Inc. announced that it expects to receive CAD 1 million in funding	Apr. 02	CI
Principal Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	Mar. 28	CI
Principal Technologies Acquiring Denmark's Vivostat for 7.5-Million Euros and 2.5-Million Shares	Feb. 06	MT
Principal Technologies Inc. entered into an arm's length binding share purchase agreement to acquire Vivostat A/S for ?7.8 million.	Feb. 05	CI
Principal Technologies Closes Third And Final Tranche Of Oversubscribed Private Placement	Jan. 19	MT
Principal Technologies Inc. announced that it has received CAD 1.498975 million in funding	Jan. 17	CI
Principal Technologies Inc. Reports Earnings Results for the First Quarter Ended October 31, 2023	Dec. 29	CI
Principal Technologies Completes 2nd Tranche; Upsizes Oversubscribed Private Placement	Dec. 22	MT
Principal Technologies Inc. Reports Earnings Results for the Full Year Ended July 31, 2023	Nov. 30	CI
Principal Technologies Brief: Announced listing of Its Common Shares on the Frankfurt Stock Exchange	23-10-16	MT
Toronto Stocks Flat; Denison Mines Rises on C$15 Million Investment in F3 Uranium	23-10-06	DJ
Principal Technologies Inc. announced that it expects to receive CAD 0.9 million in funding	23-10-05	CI
Principal Technologies Inc. announced that it has received CAD 0.301154 million in funding	23-07-05	CI
Principal Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-27	CI
Principal Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2023	23-03-31	CI
Principal Technologies Inc. Announces CFO Changes	23-03-06	CI
Principal Technologies Inc. Announces Executive Changes	23-03-06	CI
Principal Technologies Inc. announced that it expects to receive CAD 0.7 million in funding	23-03-05	CI
Principal Technologies Inc. Auditor Raises 'Going Concern' Doubt	23-02-27	CI
Principal Technologies Inc. Reports Earnings Results for the First Quarter Ended October 31, 2022	23-02-27	CI
Principal Technologies Inc. Announces Executive Changes	22-12-30	CI
Principal Technologies Inc. Announces Board Advisory Appointments	22-11-29	CI
Principal Technologies Inc. Initiates Proceedings of A Potential $500,000 Private Placement Financing	22-11-29	CI
Principal Technologies Inc. announced that it expects to receive CAD 0.5 million in funding	22-11-28	CI

Chart Principal Technologies Inc.

Duration

Period

More charts

Company Profile

Principal Technologies Inc. is a Canada-based company. The Company is engaged in building a diverse portfolio of investments in healthcare technology companies with a focus on those with global distribution potential which have intellectual property capable of enhancing medical treatment quality, cost efficiency, optimization of the patient pathway, and implementation of point of care technologies. It operates in one operational segment, being its operations in healthcare technology, including the project management of international scale clinical studies primarily related to medical device technologies. The Company's subsidiaries include Principal Technologies Capital Management GmbH and E&E CRO Consulting GmbH.

Sector

Biotechnology & Medical Research

Calendar

2024-06-24 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PRINCIPAL TECHNOLOGIES INC.	+11.11%	3.62M
MODERNA, INC.	+42.29%	54.04B
LONZA GROUP AG	+43.57%	41.96B
IQVIA HOLDINGS INC.	-1.39%	41.92B
CELLTRION, INC.	-7.59%	28.35B
ICON PUBLIC LIMITED COMPANY	+11.63%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-22.24%	19B
BIO-TECHNE CORPORATION	+7.83%	13B
MEDPACE HOLDINGS, INC.	+28.43%	12.28B
UNITED THERAPEUTICS CORPORATION	+25.67%	12.19B

Other Biotechnology & Medical Research